Actively Recruiting
Evaluating QMF149 Versus Budesonide for Asthma in Children Aged 6 to Less Than 12 Years Randomized, Double-Blind, Crossover Study with Two 12-Week Treatment Periods
Led by Novartis Pharmaceuticals · Updated on 2026-10-15
200
Participants Needed
65
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of QMF149 a combination of indacaterol acetate and mometasone furoate compared to budesonide in children aged 6 to less than 12 years who have asthma. This Phase 3, double-blind, randomized, active-controlled crossover study aims to determine whether QMF149 is superior in improving lung function measured by FEV1 in these children, who have at least 50% of the predicted normal value of FEV1. Participants undergo two treatment periods, each lasting 12 weeks, receiving either QMF149 7540 mcg once daily via Breezhaler or budesonide 200 mcg once daily via Breezhaler in a crossover design. The study includes a screening period of up to 3 weeks, a 3-week run-in period with fluticasone propionate 50 mcg twice daily, a 3-week washout period with the same medication, and a 4-week safety follow-up during which participants return to standard care. The total study duration is up to 37 weeks. Throughout the study, participants will attend visits at defined intervals, including screening, run-in, treatment, washout, and follow-up periods. Researchers will assess lung function changes FEV1, asthma control questionnaire scores, peak expiratory flow rates, rescue medication use, and monitor adverse events. Safety information and survival status will be collected after the follow-up period to ensure thorough evaluation of both treatments.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here